BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Friedlander M, Benson C, O'Connell RL, Reed N, Clamp A, Lord R, Millan D, Nottley S, Amant F, Steer C, Anand A, Mileshkin L, Beale P, Banerjee S, Bradshaw N, Kelly C, Carty K, Divers L, Alexander L, Edmondson R. Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecol Oncol 2021;161:160-5. [PMID: 33608144 DOI: 10.1016/j.ygyno.2021.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Crowley F, Cadoo KA, Chiang S, Mandelker DL, Bajwa R, Iasonos A, Zhou QC, Miller KM, Hensley ML, O'cearbhaill RE. Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas. Gynecologic Oncology Reports 2022;40:100980. [DOI: 10.1016/j.gore.2022.100980] [Reference Citation Analysis]
2 Maccaroni E, Lunerti V, Agostinelli V, Giampieri R, Zepponi L, Pagliacci A, Berardi R. New Insights into Hormonal Therapies in Uterine Sarcomas. Cancers 2022;14:921. [DOI: 10.3390/cancers14040921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Edmondson RJ, O'Connell RL, Banerjee S, Mileshkin L, Sykes P, Beale P, Fisher A, Bonaventura A, Millan D, Nottley S, Benson C, Hamilton A, Sjoquist K, Alexander L, Kelly C, Carty K, Divers L, Bradshaw N, Friedlander M; PARAGON investigators. Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecol Oncol 2021;163:524-30. [PMID: 34625284 DOI: 10.1016/j.ygyno.2021.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]